Timothy A. Yap, MBBS, PhD, MRCP, BS. ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. Presented at ASCO Annual Meeting, June 2, 2018.